ZNF595

Across TCGA pan-cancer cohorts, ZNF595 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ZNF595 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF595 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF595 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, ACC, and BRCA are the cancer types where ZNF595 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.190	0.663	<.001	48	view →
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
BRCA	OS	Median	All	0.854	0.963	.001	34	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	12	view →
SCLC	DFS	Median	II,III,IV	0.178	0.573	.016	6	view →
LUSC	OS	Median	III,IV	0.206	0.671	.010	6	view →
BLCA	DFS	Median	IV	0.077	0.476	<.001	6	view →
LUAD	DFS	Median	All	1.000	0.326	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZNF595–HNSC (OS)

Open the HNSC breakdown →